Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
- Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 -Globe Newswire
環球新聞專線
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibition than either treatment alone -
-在 AACR 上公佈的臨床前數據表明，與單獨使用任何一種療法相比，將 IMM-1-104 與用於一線胰腺癌治療的化療結合可產生更深、更持久的腫瘤生長抑制作用-
- Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting -
-患者目前正在進行的 2a 期試驗的多個組中接受治療，其中包括在一線環境中正在接受 IMM-1-104 聯合化療治療的多名胰腺癌患者-
- Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 -
-Immuneering 預計 2024 年將有來自多個 IMM-1-104 第 2a 階段組的初始數據-
